New CAR t therapy targets tough lymphoma in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target a protein called BAFFR on cancer cells. The main goals are to …
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 12:08 UTC